A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Psoriasis

In brief

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

Key facts

Study ID

NCT05730725

Run by

Bristol-Myers Squibb

People needed

109

Starts

2023-04-03

Expected to finish

2024-08-06

Last updated by the study team

2025-11-25

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of plaque psoriasis (PsO) for ≥ 6 months
• Body mass index 18 to 40 kg/m\^2 and total body weight > 50 kg (110 lbs)
• Deemed by Investigator to be eligible for phototherapy or systemic therapy
• Psoriatic plaques must cover ≥ 10% of body surface area at baseline
• Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline

You may not qualify if…

• Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)
• Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment
• Any significant acute or chronic medical illness
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0006 — Birmingham, Alabama, United States
• Local Institution - 0012 — Encino, California, United States
• Local Institution - 0005 — Fountain Valley, California, United States
• Local Institution - 0002 — Fremont, California, United States
• Local Institution - 0001 — Los Angeles, California, United States
• Local Institution - 0016 — Los Angeles, California, United States
• Local Institution - 0003 — Santa Ana, California, United States
• Local Institution - 0013 — Coral Gables, Florida, United States
• Local Institution - 0056 — Skokie, Illinois, United States
• Local Institution - 0044 — Clarksville, Indiana, United States
• Local Institution - 0057 — Leawood, Kansas, United States
• Local Institution - 0004 — Beverly, Massachusetts, United States
• Local Institution - 0060 — Lee's Summit, Missouri, United States
• Local Institution - 0007 — Portsmouth, New Hampshire, United States
• Local Institution - 0055 — Durham, North Carolina, United States
• Local Institution - 0008 — Cleveland, Ohio, United States
• Local Institution - 0058 — Rapid City, South Dakota, United States
• Local Institution - 0059 — Dallas, Texas, United States
• Local Institution - 0011 — Webster, Texas, United States
• Local Institution - 0024 — Brisbane, Queensland, Australia
• Local Institution - 0019 — Carlton, Victoria, Australia
• Local Institution - 0045 — Pascoe Vale South, Victoria, Australia
• Local Institution - 0062 — St. John's, Newfoundland and Labrador, Canada
• Local Institution - 0034 — Barrie, Ontario, Canada
• Local Institution - 0020 — Hamilton, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.